IMPORTANCE Evolutionary medicine may provide insights into human physiology and pathophysiology, including tumor biology.
T he mechanisms that prevent accumulation of genetic damage and subsequent uncontrolled proliferation of somatic cells in multicellular organisms remain poorly understood. A greater number of cells and cell divisions increases the chance of accumulating mutations resulting in malignant transformation. 1 If all mammalian cells are equally susceptible to oncogenic mutations, then cancer risk should increase with body size (number of cells) and species life span (number of cell divisions). The Peto paradox describes the observation that cancer incidence across animals does not appear to increase as theoretically expected for larger body size and life span. 2, 3 To our knowledge, the cellular mechanism for this phenomenon of cancer resistance has never been demonstrated experimentally in organisms other than rodents. [4] [5] [6] TP53 (encoding the protein p53 [RefSeq NM_000546]) is a crucial tumor suppressor gene, mutated in the majority of human cancers. 7 Referred to as the "guardian of the genome," inactivation of p53 leads to 3 cancer cell characteristics including suppression of apoptosis, increased proliferation, and genomic instability. 8, 9 Humans contain 1 copy (2 alleles) of TP53, and both functioning alleles are crucial to prevent cancer development. Absence of 1 functional allele leads to Li-Fraumeni syndrome (LFS), a cancer predisposition with more than a 90% lifetime risk for cancer, multiple primary tumors, and early childhood cancers. 10, 11 Understanding the cellular mechanism of cancer suppression in animals could benefit humans at high risk of cancer, such as patients with LFS, and even the healthy, aging population. This study investigated the cancer rate in different mammals (including elephants), identified potential molecular mechanisms of cancer resistance, and compared response to DNA damage in elephants with that in healthy human controls and individuals with LFS.
Methods
Ethical and scientific institutional review board approval was obtained from each participating research organization for all elephant and human participation, including written informed consent from human participants. Experiments were performed on peripheral blood lymphocytes (PBLs) from African and Asian elephants, from a representative clinical cohort of patients with LFS enrolled in a separate study (the Cancer Genetics Study, University of Utah), and from agematched human controls without a significant family history of cancer also enrolled in the Cancer Genetics Study. Patients with LFS were selected for inclusion as a representative sample based on TP53 mutation status, varied cancer history, and availability for blood draw. Human subject materials were collected at the University of Utah from June 2014 to July 2015. Laboratory experiments were also performed on African elephant fibroblasts, human fibroblasts, and HEK293 cells to confirm these findings.
Necropsy data were examined from zoo animals to determine if empirical evidence supports that cancer incidence does not increase with body size or life span. Fourteen years of necropsy data collected by the San Diego Zoo 12 was compiled and tumor incidence was calculated for 36 mammalian species, spanning up to 6 orders of magnitude in size and life span. 13 Data from the Elephant Encyclopedia 14 were analyzed on the cause of death in captive African (Loxodonta africana) and Asian (Elephas maximus) elephants to estimate age incidence and overall lifetime cancer risk. Using the cancer transformation model from Calabrese and Shibata, 15 the percentage decrease in cellular mutation rate was calculated to account for a 100× increase in cell mass (the difference between elephants and humans) without cancer development. Genomic sequence analysis was next performed on the publicly available scaffolds of the African elephant genome in the Ensembl database (release 72; http://www.enssemble .org/) and the NCBI Gene database (http://www.ncbi.nlm.nih .gov/gene), with examination of cancer-related genes including oncogenes and tumor suppressors. TP53 sequence alignments were explored in related species, and African and Asian elephant TP53 retrogenes were cloned and resequenced. Capillary sequencing was performed on single elephants to avoid issues of single-nucleotide polymorphisms between elephants. Whole genome sequencing (Illumina HiSeq 2500) was performed on freshly extracted DNA from an African elephant at 40× average sequence coverage, with more than 100× coverage within areas of TP53.
Functional molecular analysis of TP53 and its retrogenes was performed on peripheral blood mononuclear cells from African and Asian elephants and fibroblasts from an African elephant. To determine if TP53 retrogenes are expressed in the elephant, reverse transcription-polymerase chain reaction was performed on RNA collected from African elephant peripheral blood mononuclear cells and African elephant fibroblasts. Polymerase chain reaction primers were designed to distinguish the TP53 retrogenes from the ancestral sequence and splice variants. Human vs elephant DNA repair efficiency (measured by double-strand breaks indicated by number of phospho-histone H2AX [pH2AX] foci), apoptosis (annexin V [AV] and propidium iodide [PI] by flow cytometry and Apotox-Glo, Promega), and cell cycle arrest (Apotox-Glo, Promega) were compared at different time points (1, 5, 10, 18, 24 , and 72 hours) after DNA damage (doxorubicin, 0.005-30 μM; and ionizing irradiation, 0.5, 2, 5, 6, 10, and 20 Gy). Late apoptosis was defined as AV+PI+ and early apoptosis was defined as AV+PI−. Experiments were performed in either triplicate or quadruplicate. p53 plays a critical role in p21 and mouse double minute 2 homolog (Mdm2 or E3 ubiquitin-protein ligase Mdm2) protein induction following DNA damage, 16 ,17 so p21 immunoblots were performed to validate a p53-dependent DNA damage response in elephant cells. p53 retrogene 9 (GenBank KF715863) was cloned into an expression vector to produce a protein fused to an epitope from the Myc protein. HEK293 cells were transfected with this Myc-tagged p53 retrogene 9 expression vector and p53 retrogene protein expression was measured by immunoblot using an antibody to the Myc tag. Retrogene protein product was co-immunoprecipitated from HEK293 cell lysates with Myc antibody, followed by immunoblots for phospho-p53 (serine-15) and Mdm2. The HEK293 cell line was chosen for these experiments because it is a human cell line (human embryonic kidney) that is easy to transfect and measure protein expression. Cross-species lifetime cancer incidence was estimated by the number of animals in each species that reportedly died of cancer. A logistic regression model was fit to determine if body mass and maximum life span are variables associated with cancer incidence (R software, version 3.2.1). Additionally, all combinations of mass, life span, and mass-specific basal metabolic rate were examined for evidence of cancer association. An inverse cancer association was specifically tested in the largest existing terrestrial mammal, the elephant. For the DNA damage analysis, a χ 2 test was used to compare pH2AX foci, and an unpaired 2-sided t test with α = .05 was used for apoptosis and cell cycle arrest (R software, version 3.2.1, and GraphPad Prism, version 6.0e). Both a linear regression and a Jonckheere-Terpstra test were used to assess if apoptotic response decreased with age. Details of the experimental methods are further described in the eAppendix in the Supplement.
Results

Zoo Necropsies and Cancer Mortality
The 36 mammalian species analyzed spanned from the striped grass mouse (weight, 51 g, with a maximum life span of 4.5 years) to the elephant (weight, 4800 kg, with a maximum life span of 65 years). Cancer risk did not increase with mammalian body size and maximum life span among 36 species analyzed (eg, for rock hyrax, 1% [95% CI, 0%-5%]; African wild dog, 8% [95% CI, 0%-16%]; lion, 2% [95% CI, 0%-7%]) ( Figure 1 ). No significant relationship was found with any combinations of mass, life span, and basal metabolic rate and cancer incidence (eFigure 1 and eTable 1 in the Supplement). Among 644 annotated elephant deaths from the Elephant Encyclopedia database, the lifetime cancer incidence was 3.11% (95% CI, 1.74%-4.47%) ( Table 1) . To obtain a more conservative estimate, an inferred cancer incidence was calculated for cases that lacked adequate details for the cause of death, leading to an estimated elephant cancer mortality rate of 4.81% (95% CI, 3.14%-6.49%). Based on an algebraic model of carcinogenesis, 15 a 2.17-fold decrease in mutation rate was calculated as sufficient to protect elephants from cancer development given their 100× increased cellular mass compared with humans. 
African Elephant Genome Analysis
The African elephant (L africana) draft genome LoxAfr3 contains 19 copies of TP53. The human haploid genome contains 1 copy of TP53, while Ensembl and GenBank annotate a large number of TP53 paralogs in the African elephant genome (12 and 20 haploid copies, respectively; eTable 2 in the Supplement). Elephant sequence alignments revealed 1 TP53 copy with a comparable gene structure to TP53 found in other mammalian species (ancestral copy). The other 19 copies lack true introns, suggesting that they originated from retrotransposition (retrogenes). Cloning and resequencing confirmed at least 18 distinct retrogene copies in the African elephant in a maximum likelihood phylogeny, supported by multiple clones clustered into 2 main subtrees (groups A and B; Figure 2 ). Whole-genome sequencing with deep coverage confirmed 1 ancestral copy and 19 total retrogene copies, similar to the TP53 20 total copies annotated in GenBank. Eleven of the 18 retrogenes from the capillary sequencing were similar but not identical to previous GenBank annotations and local whole genome sequencing data (eTable 2 in the Supplement). High variance in coverage across reference TP53 copies may indicate additional TP53 elephant copies not yet successfully assembled. There was no evidence for 8 of the published retrogene copies, possibly because of undersampling of clones, misassembly in the published genome, or differences between individual elephants. An additional 7 cloned sequences had support from multiple clones but were not found in either database. Further TP53 copies in the genome may also have been undetected by the polymerase chain reaction primers. The Asian elephant DNA was also found to contain 15 to 20 copies of group A and B TP53 retrogenes (eFigure 2 in the Supplement).
TP53 Retrogene Transcription and Translation
Reverse transcription-polymerase chain reaction on RNA from African elephant peripheral blood mononuclear cells and fibroblasts exposed to 2 Gy of radiation demonstrated TP53 retrogene expression. Products of the expected sizes were observed, separating the 2 groups of retrogenes (eFig- A maximum likelihood phylogeny was used to cluster the sequenced TP53 retrogene clones and to confirm the number of unique genes uncovered in the African elephant genome. The phylogeny allows for visualization of TP53 retrogene similarity to one another as well as their relationship to the ancestral TP53 sequence in the elephant and hyrax. The capillary sequenced clones from this study are shown as black circles and published sequences from GenBank are shown as red squares. Gene identifiers and genomic coordinates are given in eTable 2 in the Supplement. Phylogenic analysis reveals at least 18 distinct clusters of processed TP53 copies (shown as colored blocks numbered 1 to 18). These clusters fall into 2 groups, labeled group A and group B. The branch labeled "elephant" is the coding sequence of the ancestral TP53, and "hyrax" represents the coding sequences from the hyrax TP53. The hyrax, on the upper left, is used as the outgroup to show that the hyrax and elephant ancestral TP53 sequences are more similar to each other than to the retrogenes, and also that the retrogenes evolved after the split between hyrax and elephant. The distances between the retrogene sequences display their relationship based on sequence similarity but do not represent precise evolutionary time estimates. These data were generated with DNA from 1 elephant to control for polymorphic bases between individual elephants.
PBLs, indicating that the increased apoptosis in elephants cannot be attributed to more DNA damage (Table 2, Figure 5 , and eFigure 7 in the Supplement). This increased apoptosis was observed in different lymphocyte wash conditions (eFigure 8 in the Supplement). Unlike increasing TP53 mRNA levels seen in human PBLs after ionizing radia- tion, gene expression of ancestral and retrogene TP53 did not increase in elephant PBLs (eFigure 9 in the Supplement). Both elephant and human PBLs showed p53 and p21 protein expression following ionizing radiation exposure ( Figure 6 ). More p21 protein expression was observed at 5 hours in elephant PBLs treated with 0.5 Gy of ionizing radiation (20.1-fold increase; 95% CI, 8.72-to 31.5-fold) compared with human PBLs (3.5-fold increase; 95% CI, 1.7-to 5.31-fold; P = .004) (eFigure 10, A-B, in the Supplement). Elephant fibroblasts also showed increased p21 protein expression following 2 Gy of ionizing radiation at 5 hours (1.9-fold increase) compared with no increase in human fibroblasts (eFigure 10C in the Supplement). Similar to lymphocytes, elephant vs human fibroblasts showed evidence of increased apoptosis after 10 μM of doxorubicin as measured by increased caspase activity relative to dimethyl sulfoxide-treated fibroblasts (elephant: 9. As a post hoc analysis, the same experiments were repeated in PBLs from multiple Asian elephants (n = 6) of different ages (2, 12, 17, 38, 57 , and 69 years old). Asian elephant lymphocytes also demonstrated an increased rate of apoptosis (50.63%; 95% CI, 41.71%-59.53%) relative to human cells (23.67%; 95% CI, 21.18%-26.15%; P < .001) when exposed to 2 Gy of ionizing radiation (18-hour culture) and an increase in p21 expression ( Figure 7, A-B) . Additionally, the apoptotic response in PBLs decreased with the age of Asian elephants when tested with both a linear regression and a JonckheereTerpstra test, which allows for nonlinear relationships ( Figure 7C) 
Discussion
Peto first made the observation more than 35 years ago that larger and longer-lived mammals develop less cancer than expected, 3, 23, 24 but the evolutionary and functional mechanisms for this phenomenon have been studied only in rodents. [4] [5] [6] To our knowledge, this study offers the first supporting evidence based on empirical data that larger animals with longer life spans may develop less cancer, especially elephants. The cancer mortality rate for elephants was found . The healthy control lymphocytes underwent more apoptosis than those from LFS patients (P < .001), and elephant lymphocytes underwent more apoptosis than those from healthy controls (P < .001 by 2-sided t test). Horizontal lines indicate the combined mean for all data points in each group with error bars indicating 95% CIs. was identified in elephants, and the effect TP53 amplification may have on apoptotic response to DNA damage was explored. These findings support the concept of an evolutionary-based approach for cancer suppression. TP53 plays a central role in cancer suppression and response to DNA damage through apoptosis and cell cycle arrest. 8, 26, 27 Patients with LFS inherit only 1 functioning TP53 allele and may have a lifetime risk of cancer approaching 100%. 10, 11 Conversely, inserting additional copies of constitutively active TP53 in mice confers cancer resistance with accelerated aging, 28 while redundant TP53 alleles under the endogenous promoter generate cancer-resistant laboratory mice that age normally. 29 The evolution of the elephant would have involved a strong selective pressure to naturally suppress cancer in a long-lived animal 100 000 times the size of a mouse. Female elephants reproduce and raise offspring throughout their entire life span of 50 to 80 years, older males have higher status and more reproductive opportunities, 30 and herds with older matriarchs may have higher fitness. 31 The enormous mass, extended life span, and reproductive advantage of older elephants would have selected for an efficient and fail-safe method for cancer suppression. The multiple copies of TP53 and the enhanced p53-mediated apoptosis observed in elephants may have evolved to offer such cancer protection. The data suggest a lower threshold for DNA damage before triggering p53-dependent apoptosis in elephants than in humans, a possible evolutionary strategy to avoid cancer by efficiently removing mutant cells. Consistent with previous evidence that increasing TP53 gene dosage increases rates in lymphocytes increased proportionally among patients with LFS (1 TP53 functioning allele), human controls (2 TP53 alleles), and elephants (40 TP53 alleles). Elephant cells exposed to DNA damage showed increased p21 expression, a downstream target of p53 activation. Also, p53 retrogenes were up-regulated and translated when transfected into human cells treated with ionizing radiation and doxorubicin. These combined observations suggest that the increased cell death in elephants may be mediated by p53 and enhanced by the additional TP53 retrogenes.
Retrotransposed genes, often called pseudogenes, can play functional roles in biology. 32, 33 Based on the study results, the TP53 retrogenes may functionally increase elephant cell response to DNA damage by triggering p53-dependent apoptosis rather than increasing DNA repair. Apoptosis can prevent mutations from propagating to future cell generations through removal of mutated clones. The elephant cells appeared twice as sensitive to DNA damage-induced apoptosis as human cells. Increasing apoptosis effectively lowers the ongoing mutation rate for the entire cell population and, as calculated, this 2-fold decrease in the somatic mutation rate (doubling of apoptosis) in elephants could explain the 100× increase in cell mass without cancer transformation. 1 5 ,3 4 The Asian elephant genome contained 15 to 20 TP53 retrogene copies, suggesting that TP53 retrogene amplification predated the split of the African and Asian elephant species approximately 6.6 million to 8.8 million years ago. 35 The hyrax (Procavia capensis) is the closest elephant relative with an available genome assembly (proCap1) and contains only 1 copy (2 alleles) of TP53. The hyrax and elephant lineages diverged 54 million to 65 million years ago, 36 making this time frame the upper bound of when these TP53 retrogenes evolved.
A consistent age-related decrease in apoptosis was found in Asian elephants. Age-related decline in apoptotic response has been observed in murine T cells, 37 human PBLs, 38 and human sperm. 39 Young elephants rapidly grow in less than 10 years from a birth weight of 100 kg to more than 3000 kg at reproductive age, a 30-fold increase in cellular mass with more than 1 kg of weight gain per day. Such a high rate of cell division and expansion in the growing elephant requires an especially efficient system of cancer prevention. The study of cancer and apoptosis across species has several limitations. Cancer mortality rates in humans are often reported as deaths per 100 000 per year, 25 and sufficient sample sizes of animals are difficult to find for comparison. The cross-species mortality rates in this study included estimates based on small numbers of captive animals with wide confidence intervals. More data need to be collected to confidently demonstrate the absence of correlation of mass and life span with cancer mortality. Environmental factors also play a role in cancer development, and it is unclear how captivity influences cancer rates through diet, stress, physical activity, and reproduction. The expected life span of captive African and Asian elephants is decreased, 40 and this analysis may not have fully captured the elderly elephant population most expected to develop cancer. Adding to the complexity, humans are treated with modern medicine and may have an artificially extended life span, which, along with carcinogenic exposures like smoking, increases the lifetime risk of cancer death. Neither the African nor Asian elephant genome has been formally assembled and, consequently, elephant-specific molecular agents such as phosphorylated p53 elephant antibodies to measure elephant p53 activation are challenging to obtain. Studying the p53 pathway requires certain assumptions, such as that p21 and Mdm2 protein levels truly reflect p53 activity, as they do in humans. Although the data are sug- 
